Journal ArticleOPEN ACCESS

Is tenofovir/emtricitabine teratogenic?

Therapeutic Advances in Drug Safety (2013) 4(3) 115-117
DOI: 10.1177/2042098613485276
3Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The Truvada® (tenofovir/emtricitabine) and nevirapine combination is increasingly being prescribed for prevention of mother-to-child HIV transmission. There is presently no documented evidence of teratogenicity of either tenofovir/emtricitabine or nevirapine. We report two cases of spina bifida in infants of mothers on this drug combination. © 2013, SAGE Publications. All rights reserved.

Author supplied keywords

Cite

CITATION STYLE

APA

Jibril, M., & Egunsola, O. (2013). Is tenofovir/emtricitabine teratogenic? Therapeutic Advances in Drug Safety, 4(3), 115–117. https://doi.org/10.1177/2042098613485276

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free